智通财经APP获悉，继昨日股价大涨逾13%之后，周五，再鼎医药(ZLAB.US)再度大涨逾10%，报23.03美元。消息面上，花旗发表报告称，再鼎医药二季度产品收入按季改善约11%至约1.06亿美元，符合该行和市场预期，令该行更有信心其中国业务可于2026年下半年企稳，并按管理层指引于2027年恢复显著增长。该行将再鼎医药美股目标价由44美元上调至45美元。
智通财经APP获悉，继昨日股价大涨逾13%之后，周五，再鼎医药(ZLAB.US)再度大涨逾10%，报23.03美元。消息面上，花旗发表报告称，再鼎医药二季度产品收入按季改善约11%至约1.06亿美元，符合该行和市场预期，令该行更有信心其中国业务可于2026年下半年企稳，并按管理层指引于2027年恢复显著增长。该行将再鼎医药美股目标价由44美元上调至45美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.